Skip to content

Cro services in


Gubra is industry-leading in translational models of non-alcoholic steatohepatitis (NASH*) and NASH-driven hepatocellular carcinoma (NASH-HCC). Our automated AI-based histology pipeline enables effective, accurate and objective analysis of drug effects on pivotal clinical endpoints.

*Metabolic dysfunction-associated steatohepatitis (MASH) is now the replacement term for NASH.

Why Gubra?
  • Expert scientific guidance in NASH/MASH
  • Clinically translatable models
  • GAN DIO-NASH (GAN DIO-MASH) mouse ranked #1 by LITMUS consortium
  • Biopsy-enabled stratification of baseline disease
  • Profile compounds using clinical trial endpoints
  • Tailored study design and rapid initiation

Consult with Michael Feigh

Vice President, Scientific Sales

Choose the right animal model for your NASH/MASH-targeted drug candidate.

What is MASH?

Metabolic Dysfunction-associated Steatohepatitis (MASH)

The terms non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) will now be replaced by MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis).

Industry-leading models for translatability into the clinic

Choosing the right translational NASH/MASH model is crucial for efficacy evaluation and bridging to clinical development. Our GAN DIO-NASH (GAN DIO-MASH) mouse model has been ranked #1 by the LITMUS consortium for its human proximity score and clinical translatability. Our model is already induced and ready to be used for your study immediately. All animals are biopsy-confirmed for stratification of baseline disease.

Main Offerings

Full metabolic

Biochemical assessment
liver & plasma

NAS & fibrosis scoring

Quantitative histology
Steatohepatitis & fibrosis

Hepatic transcriptomic

readily available

High clinical translatability

Models of NASH/MASH & NASH/MASH-driven HCC

Related pages

For further information

Contact us


Hørsholm Kongevej 11B
2970 Hørsholm

+45 3152 ­2650

Back To Top